Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
22,927,577
-
Total 13F shares
-
17,996,162
-
Share change
-
+4,531,984
-
Total reported value
-
$151,883,912
-
Price per share
-
$8.44
-
Number of holders
-
51
-
Value change
-
+$39,427,360
-
Number of buys
-
31
-
Number of sells
-
11
Institutional Holders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) as of Q4 2025
As of 31 Dec 2025,
Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,996,162 shares.
The largest 10 holders included
SAMSARA BIOCAPITAL, LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, Siren, L.L.C., Alyeska Investment Group, L.P., Ikarian Capital, LLC, VANGUARD GROUP INC, Kalehua Capital Management LLC, Woodline Partners LP, and ADAR1 Capital Management, LLC.
This page lists
51
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.